BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15658471)

  • 1. [Monoclonal antibody therapy and laboratory medicine].
    Takeshita A
    Rinsho Byori; 2004 Nov; 52(11):917-23. PubMed ID: 15658471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
    Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M
    Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
    Jurcic JG
    Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibody directed therapy for leukemia].
    Takeshita A; Naito K; Ohno R
    Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
    Voutsadakis IA
    Anticancer Drugs; 2002 Aug; 13(7):685-92. PubMed ID: 12187324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.